Who is Dr. David Knopman? A second renowned doctor resigns over FDA’s approval of aducanumab

June 16, 2021

David-Knopman-13632736

Dr. David Knopman, a neurologist at the Mayo Clinic and member of the FDA advisory panel on nervous system drugs, resigned on June 9.

He was the second doctor on the panel to resign over the FDA’s approval of aducanumab for treatment of Alzheimer’s disease. Dr. Joel Perlmutter resigned the same day that the FDA approved the drug.

 

What did we learn about Dr. Knopman from searching in ResoluteAI’s Foundation?

Dr. Knopman has been an author of over 700 publications. His five most recent research articles are:

The heatmap below shows where- and on what topics- he has published over just the past five years. During this time, he has published most frequently on Pittsburgh compound B, a radioactive compound created in 2008 used for early diagnosis of Alzheimer’s disease.

Screen Shot 2021-06-15 at 12.15.31 PMDr. Knopman’s publications by tag and journal name, 1/1/16-1/1/21

Dr. Knopman has received 16 grants, involving diseases like Parkinson’s disease, dystonia, and dementia:

His grants have covered a wide range of topics as the Sankey diagram below illustrates.

Dr. Knopman’s grants by tag and category for the period 1/1/16-1/1/21

Additionally, he has had his work cited in over 15 patents involving dementia and Alzheimer’s. Some of these patents are:



Research across all of these databases was conducted quickly and efficiently using ResoluteAI’s Foundation. To talk to a real person about how Foundation can help your company or organization, please email us at info@resolute.ai.

Let's talk

Lesley Pink

Lesley Pink, our senior digital editor/writer, has written across a range of industries including artificial intelligence, actuarial science, government, law, and financial journalism. She's a fan of the serial comma and mint chocolate chip ice cream. And no, pink is not her favorite color. You can reach Lesley at lesley@resolute.ai.